Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Bart Westerman
Divergent genomic evolution in astrocytomas and oligodendrogliomas
Abstract Astrocytomas and oligodendrogliomas are isocitrate dehydrogenase (IDH)-mutant gliomas that most commonly arise in adults under the age of 50 and exhibit variable responses to treatment1,2,3. To understand the genetic drivers of disease progression, here we used whole-genome and whole-exome sequencing to characterize longitudinally collected tumour specimens from 183 patients with IDH-mutant glioma. Samples were collected through the Glioma Longitudinal Analysis (GLASS) Consortium4.
Challenges to determine synergistic drug interactions in mice - Nature Communications
arising from R. S. Narayan et al. Nature Communications https://doi.org/10.1038/s41467-020-16735-2 (2020) Synergistic drug interactions can be assessed in a laboratory setting by multiple methods that do not necessarily lead to the same outcome; hence, the optimal way to determine synergy is a matter of an ongoing debate.
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling - Nature Cancer
Abstract The evolutionary processes that drive malignant progression of IDH-mutant astrocytomas remain unclear. Here, we performed multiomics on matched initial and recurrent tumor samples from a cohort of 105 patients and overlaid the data with detailed clinical annotation. We identified overlapping features associated with malignant progression that are derived from three molecular mechanisms: cell cycling, tumor cell (de)differentiation and remodeling of the extracellular matrix.
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets
|
1Amsterdam UMC, location Vrije Universiteit Amsterdam, Department of Medical Oncology, OncoProteomics Laboratory, De Boelelaan 1117, Amsterdam, the Netherlands 2Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands 3School of Medicine, Westlake University, Hangzhou, Zhejiang, China 4Westlake Center for Intelligent Proteomics, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China 5Amsterdam UMC location Vrije Universiteit Amsterdam, Department of...
By Jaco C. Knol, Mengge Lyu, Franziska Böttger, Madalena Nunes Monteiro, Thang V. Pham, Frank Rolfs, Andrea Vallés-Martí, Tim Schelfhorst, Irene V. Bijnsdorp, Shuaiyao Wang, Fangfei Zhang, Bart Westerman, Barbara Sitek, Janne Lehtiö, Jan Koster, Jan IJzermans, Maarten F. Bijlsma, Jan Paul Medema, Alex A. Henneman, Sander R. Piersma, Ruud H Brakenhoff, Jacqueline Cloos, Valentina Cordo', Daphne de Jong, Geert Kazemier, Danijela Koppers-Lalic, Mariette Labots, John Martens, Jules P.P. Meijerink, Madiha Mumtaz, Chantal Scheepbouwer, Robby E. Kibbelaar, David P. Noske, Renske D.M. Steenbergen, Winan van Houdt, Elisa Giovannetti, Jos Jonkers, tong liu, Meisi Yan, Xiaolu Zhan, Tiannan Guo, Connie R. Jimenez
|
Cell Press
Verified
Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytoma - Nature Communications
Abstract Isocitrate dehydrogenase 1/2 mutant (IDHmt) astrocytoma is considered a T cell-deprived tumor, yet little is known regarding the phenotypes underlying T cell exclusion. Using bulk, single nucleus and spatial RNA and protein profiling, we demonstrate that a distinct spatial organization underlies T cell confinement to the perivascular space (T cell cuff) in IDHmt astrocytoma.
Evaluation of SURUS: a Named Entity Recognition System to Extract Knowledge from Interventional Study Records
Casper Peeters and Koen Vijverberg are current employees of Medstone Holding BV, as was Dr. Marianne Pouwer at the time the study was conducted. This work was funded by Medstone Holding BV, Almere, the Netherlands. Bart Westerman is supported by Health~Holland under the grant called the toxicity atlas. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bart
Contact Bart, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack